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Methylenetetrahydrofolate reductase (MTHFR) catalyzes the 
reduction of 5,10-methylenetetrahydrofolate (CH2-H4 folate) 
to 5-methyltetrahydrofolate (CH3-H4 folate), as shown in 
Equation (1). 
CH2-H4 folate + NAD(P)H → CH3-H4 folate + NAD(P)+   (1)
A noncovalently bound flavin adenine dinucleotide (FAD) 
cofactor accepts reducing equivalents from NAD(P)H and 
transfers them to CH2-H4 folate. Reduction of CH 2-H4 folate 
by MTHFR is the only route for synthesis of the CH3-H4 folate 
that is utilized by methionine synthase to convert homocyste-
ine to methionine.
Deficiency of MTHFR is the most common inborn error 
of folate metabolism and is a major genetic cause of hyper-
homocysteinemia. One polymorphism, A222V (base change 
677C→T), for which ~10% of the population is homozygous,1, 
2, 3, 4 is associated with mildly elevated fasting plasma homo-
cysteine levels, especially in patients with low folate levels5, 6, 
7, and with reduced specific activity and increased thermola-
bility of MTHFR in lymphocyte extracts.1, 8 Homozygosity for 
the 677C→T mutation is the most common genetic cause of 
mildly elevated plasma homocysteine7, 9 and is a risk factor for 
the development of cardiovascular disease.1, 2, 3 The T/T geno-
type in either the mother or the fetus is also a risk factor for 
fetal neural tube defects.10 Folic acid treatment decreases ho-
mocysteine levels11 and dramatically reduces the incidence of 
neural tube defects.12 The molecular bases for the impairment 
engendered by the 677C→T mutation and for the beneficial ef-
fects of folate are addressed here.
Human and other eukaryotic MTHFRs are dimeric enzymes 
composed of subunits of Mr 70,000−77,000. Determinants for 
binding of FAD, NAD(P)H and CH2-H4 folate are located in the 
N-terminal, Mr 40,000 portion; the C-terminal domain regulates 
enzyme activity in response to the demand for adenosylme-
thionine (AdoMet) and contains the binding site for this allo-
steric inhibitor. The subunits of MTHFRs of enteric bacteria are 
shorter chains ~300 residues in length. Their sequences can be 
aligned with the N-terminal catalytic domains of the eukaryotic 
MTHFRs13, with 30% identity between the human and E. coli se-
quences (Figure 1). This level of primary sequence conservation 
predicts that the catalytic domains of the human and E. coli en-
zymes will possess similar structures.14
Many of the clinically significant mutations found so far in 
human MTHFR,1, 13, 15, 16 including A222V, affect conserved 
residues in the catalytic domain. Human MTHFR has not 
yet been expressed at high enough levels to permit purifica-
tion and biochemical investigation, so to investigate the mo-
lecular basis for impaired function in mutant human MTH-
FRs we have undertaken analyses of the enzyme from E. coli. 
The A222V mutation has been mimicked by constructing the 
corresponding A177V mutation in E. coli, and we have com-
pared the biochemical properties of the bacterial wild-type 
and A177V mutant MTHFR proteins. The X-ray structure of 
the wild-type MTHFR from E. coli , reported here, provides a 
framework to relate genotypes to molecular phenotypes.
The structure of MTHFR
The structure of MTHFR, the first example of a β8α 8 bar-
rel that binds FAD (Figure 2), has been solved using multi-
wavelength anomalous diffraction (Table 1). The chain tracing 
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Abstract
Elevated plasma homocysteine levels are associated with increased risk for cardiovascular disease and neural tube defects in humans.
Folate  treatment decreases homocysteine levels and dramatically reduces the incidence of neural tube defects. The flavoprotein 
methylenetetrahydrofolate reductase (MTHFR) is a likely target for these actions of folate. The most common genetic cause of mildly 
elevated plasma homocysteine in humans is the MTHFR polymorphism A222V (base change C677→T). The X-ray analysis of E. coli 
MTHFR, reported here, provides a model for the catalytic domain that is shared by all MTHFRs. This domain is a β8α8 barrel that 
binds FAD in a novel fashion. Ala 177, corresponding to Ala 222 in human MTHFR, is near the bottom of the barrel and distant from 
the FAD. The mutation A177V does not affect Km or kcat but instead increases the propensity for bacterial MTHFR to lose its essential 
flavin cofactor. Folate derivatives protect wild-type and mutant E. coli enzymes against flavin loss, and protect human MTHFR and the 
A222V mutant against thermal inactivation, suggesting a mechanism by which folate treatment reduces homocysteine levels.
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(Figure 2c) includes 273 residues; 20 N-terminal and two C-
terminal residues are not visible in any of the three chains that 
compose the asymmetric unit. As expected for enzymes that 
form β/α barrels, the cofactor is bound at the C-termini of the 
β-strands. The flavin ring lies within the barrel with its plane 
parallel to the staves of the barrel and its si face exposed to sol-
vent. The ribityl side chain and phosphate moieties are inserted 
between barrel strands 4 and 5, the ribosyl group adjoins helix 
5, and the adenosyl group extends over the rim of the barrel.
Other known flavoenzymes that adopt β/α barrel folds bind 
flavin mononucleotide (FMN) rather than FAD. These enzymes 
— glycolate oxidase,17 flavocytochrome b2 (18), old yellow en-
zyme,19 trimethylamine dehydrogenase,20 and dihydroorotate 
dehydrogenase21 — catalyze a variety of reactions, but FMN 
is bound in a similar fashion in all of them. Comparison of 
MTHFR with these enzymes shows that MTHFR breaks most 
of the structural rules that seemed to be established from the 
barrels that bind FMN. In the FMN-binding barrels, the ribityl 
phosphate side chain is inserted between strands 7 and 8, and 
the FMN phosphates are hydrogen-bonded to amides in the ini-
tial turn of a short but conserved helix, α8’, that precedes the 
α8-helix of the barrel. In MTHFR the ribityl side chain extends 
between barrel strands 4 and 5; there is no equivalent to the 
α8’ helix that binds the FMN phosphates, and the flavin ring 
is tilted by ~80° from its orientation in the other β8α8 flavoen-
zymes. The novel aspects of FAD binding in the MTHFR β8α 
8 barrel make it difficult to argue for divergent evolution of a 
flavin-binding family of barrel enzymes.
From the side view (Figure 2b), it is evident that strand 8 
and helix 8 are both truncated relative to the rest of the β/α 
elements of the barrel. This truncation opens a groove run-
ning from the outer edge of the barrel to the accessible si face 
of the flavin. The pyridine nucleotide and folate substrates, 
NADH and CH2-H4 folate, are each expected to bind with the 
nicotinamide or pterin rings stacked over the open face of the 
isoalloxazine ring of the FAD to facilitate hydride 
transfer. Hydride transfer between the substrates 
and the flavin N(5) is known to occur at the si face 
of the flavin ring22. Model building suggests that the 
p-aminobenzoyl-glutamate moiety of methylenetetra-
hydrofolate lies in the groove. Thus the unusual trun-
cation of the barrel elements β8 and α8 may be asso-
ciated with the requirement to bind and react with 
the folate substrate.
The FAD-binding site
Electron density corresponding to the flavin ring 
and its protein environment has been calculated 
(Figure 3a), and the interactions of bound FAD with 
some of the conserved residues that form the bind-
ing site are depicted in a stereo drawing (Figure 
3b). The residues that bind FAD are clustered at the 
ends of barrel strands β3, β4, and β5 and along he-
lix α5 (Figs 1, 3b). The composition and spacing of 
these MTHFR sequences do not correspond to the 
characteristic sequence fingerprints associated with binding of 
flavin nucleotides19, 23. The backbone of FAD is crimped by a 
kink that buries the pyrophosphate and brings the C5 atoms 
of the ribityl and ribose groups into van der Waals contact. In 
contrast to many other flavoenzymes, MTHFR does not bind 
the flavin phosphate at the initial turn of an α-helix.
An intriguing feature of the FAD-binding site is the belt 
of side chains arching over the ribityl and phosphate groups 
and secured by the Arg 118−Glu 158 interaction that acts as a 
buckle (Figure 3b). The position of these residues suggests a 
role for the belt in the thermodynamics and kinetics of FAD 
binding. The β5-α5 connector, which includes Glu 158 from 
the belt buckle, encloses the ribityl-diphosphate-ribose seg-
ments of the FAD, so rearrangements of the protein must 
occur to let FAD enter or leave its binding site. One of the 
severe mutations in human MTHFR, R157Q (base change 
482G→A) (13), alters the belt residue corresponding to Arg 
118 in E. coli MTHFR. The role of Arg 118 in the structure 
of E. coli MTHFR strongly suggests that the R157Q mutant is 
defective in flavin binding.
Characterization of A177V mutant bacterial MTHFR.
The clinically significant A222V polymorphism in human 
MTHFR has been mimicked in the E. coli enzyme by intro-
ducing the homologous mutation A177V. When the catalytic 
properties of the wild-type and A177V mutant enzymes were 
compared, the mutation was found not to affect kcat or the K m 
values for CH2-H4 folate or NADH. The kinetic parameters of 
the wild-type enzyme were determined at 15 °C and pH 7.2 in 
a stopped-flow spectrophotometer24: Km for NADH is 17 μM, 
Km for CH2-H4 folate is 3.9 μM, and kcat is 1,410 mol NADH 
oxidized min−1 (mol enzyme-bound FAD)−1. The A177V mu-
tation does not significantly change the measured kinetic pa-
rameters of MTHFR: Km for NADH is 17 μM, Km for CH2-H4 
folate is 3.9 μM, and kcat is 1,180 min−1. 
Figure 1. Alignment of the sequences of E.coli and human 
MTHFRs, based on simultaneous alignment of 12 MTHFR 
sequences and the positions of secondary structures in 
the E.coli enzyme. The locations of helices and β-strands in 
the structure are indicated by cylinders and arrows; residues 
flagged with asterisks interact with FAD in E. coli MTHFR. 
Shaded residues are identical in at least 9 of the 12 aligned 
MTHFR sequences. Sites of known mutations in the human 
enzyme are designated by black backgrounds, and the corre-
sponding amino acid and nucleotide changes are shown. The 
N-terminal methionine is removed from the mature enzyme.
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Studies of the human A222V polymorphism have sug-
gested that the mutant protein is more thermolabile than the 
wild-type protein as assessed by measurements of residual 
activity after heating lymphocyte extracts for 5 min at 46 °C 
(25) and by similar measurements with recombinant mutant 
human enzyme expressed in E. coli.1 We investigated whether 
the A177V mutation was associated with thermolability of 
the bacterial enzyme using differential scanning calorimetry. 
The Tm was 53.8 °C for 60 μM mutant enzyme and 60.9 °C for 
wild-type protein at the same concentration (Figure 4). Both 
wild-type and mutant enzymes denature at progressively 
lower temperatures as their concentrations are decreased. 
Concentration-dependent melting temperatures are expected 
for systems in which an oligomer denatures to form unfolded 
protomers26. 
Gel filtration was used to demonstrate that E. coli MTHFR 
is a tetrameric enzyme that dissociates to dimers rather than 
monomers on dilution. When wild-type or A177V enzymes 
were applied to a Superose 12 FPLC column at an initial 
concentration of 60 μM, the relative molecular masses de-
termined from the elution volumes were 119,000 ±2,000 (3.5 
±0.1 subunits mol−1 ) for the wild-type enzyme and 108,000 
±10,000 for the mutant. The flavin cofactor remained bound to 
the tetrameric enzymes during the gel filtration as indicated 
by the flavin absorbance at 450 nm. Dilution of wild-type or 
mutant enzymes resulted in dissociation to dimers and loss of 
flavin. Dissociation to dimers is consistent with the arrange-
ment of subunits found in the crystal structure. When the 
enzymes were applied to the gel column at initial concentra-
tions of 500 nM, the estimated relative molecular masses were 
65,000 ±7,000 (1.9 ±0.2 subunits mol−1) for wild-type enzyme 
and 59,000 ±4,000 for the mutant enzyme. The flavin was re-
leased and eluted later, as indicated by monitoring flavin 
fluorescence.
These observations prompted further in-
vestigation of FAD binding by the A177V 
mutant and wild-type enzymes. FAD bound 
to MTHFR is not fluorescent; dissociation 
of FAD was therefore followed by measur-
ing the fluorescence associated with the ap-
pearance of free flavin. The initial rate of fla-
vin loss from the mutant was ~11 times that 
seen with the wild-type enzyme ( Figure 5a, 
inset). The final fluorescence after dilution of 
the mutant protein to 500 nM indicated that 
all the flavin had been released. The enzyme 
concentration at which 50% of the flavin dis-
sociated was 1.3 μM for the wild-type enzyme 
and 5.9 μM for the mutant protein. These data 
imply that the A177V mutation decreases the 
affinity of the protein for FAD. In both mutant 
and wild-type enzymes the initial rate of FAD 
loss varies as the square root of the enzyme 
concentration after dilution, as indicated by the fit of the data 
to the solid lines (Figure 5a). This dependence would be ex-
pected if the dissociation of the tetramer into dimers precedes 
the release of flavin. We conclude that the A177V mutation in 
the E. coli enzyme shifts the overall equilibrium between holo-
enzyme tetramers and apoenzyme dimers toward the forma-
tion of apoenzyme dimers.
Because FAD is an essential reactant in the enzyme-cata-
lyzed electron transfer from NADH to CH2-H4 folate, flavin 
dissociation is accompanied by loss of enzyme activity. En-
zyme activity was monitored under the same conditions as 
those used for the fluorescence measurements (Figure 5a). The 
A177V protein lost activity at a rate 10 times that for the wild-
type protein, and the half-time for activity loss was the same 
as the half-time for the increase in flavin fluorescence, within 
the precision of the measurements (data not shown).
Since folate is known to lower homocysteine levels in the 
plasma, and to protect against the development of neural tube 
defects, we examined the effects of added folates on the rate 
of flavin dissociation and loss of enzyme activity after dilution 
of reductase. Addition of CH3-H4 folate (monoglutamate) re-
duced the rate of flavin loss from both the wild-type and mu-
tant enzymes in a concentration-dependent manner (Figure 5 
b). The mutant enzyme requires much higher levels of folate 
to decrease the initial rates of flavin loss to the values found 
for wild-type. When activity rather than fluorescence was 
measured following dilution into a solution containing added 
folate derivatives, in an experiment similar to that just men-
tioned (Figure 5b), the rate of loss of activity was decreased 
(data not shown). For E. coli MTHFR equivalent concentra-
tions of CH3-H4 folate triglutamate were more effective than 
the monoglutamate at reducing the rate of flavin loss, consis-
tent with the known Km values for polyglutamate substrates.27 
Protection was also observed using the inhibitor dihydrofolate 
Figure 2. The structure of E. coli MTHFR. a) A 
view along the axis of the β8α 8 barrel looking to-
ward the C-terminal ends of the β−strands37. FAD is 
drawn in ball-and-stick mode. Helix α5, which pre-
cedes the site corresponding to the human A→V 
polymorphism, is colored red in this and succeeding 
figures. b) A view perpendicular to the barrel axis 
and toward the si face of the flavin ring, showing 
the truncation of strand β8 and helix α8 and the re-
sulting groove in which methylenetetrahydrofolate 
is expected to bind. Ala 177, the site of the Ala→Val 
mutation, is drawn with gray dot surfaces, and is 
at the rear of the barrel. c) A stereo drawing of the 
chain fold from approximately the same perspective 
as in ( a).
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monoglutamate and the folate antagonist 5,10-dideazatetrahy-
drofolate pentaglutamate. We infer that any folate derivative 
that binds MTHFR slows the rate of dissociation of the flavin.
Mapping the A177V mutation onto the structure: the mo-
lecular phenotype 
The A177V mutation affects FAD binding, but alters a resi-
due that is not part of the FAD-binding site. In the E. coli en-
zyme, Ala 177 is located near the bottom of the β8α8 barrel, out 
of direct contact with the flavin or with conserved residues 
that may be essential for activity or folate binding (Figs 2b, 
6). This residue nestles in the loop connecting helix α5 with 
strand β6 and packs against atoms of Lys 172 in the preceding 
turn of the α5-helix, and against conserved residues Val 136 in 
helix α4 and Val 149 in strand β5. Mutating Ala 177 to valine 
is expected to perturb all of these packing interactions and to 
affect the secondary structures in which the neighbors of resi-
due 177 reside. Propagation of packing changes to the FAD-
binding site is easiest to envision as a perturbation of helix α5, 
which carries residues Lys 172, Asn 168, and Asp 165 that in-
teract with the phosphate and ribosyl groups of the FAD (Fig-
ure 6a). 
Interactions between chains of the tetrameric bacterial 
MTHFR may also be affected by the A177V mutation. The 
packing of chains in the tetramer of E. coli MTHFR is unusual 
(Figure 6b). The 12 monomers of the unit cell are arranged in 
layers in which either of two approximately planar arrange-
ments of four chains can be selected as the tetramer that 
exists in solution. The tetramer we have desig-
nated has larger subunit−subunit contact areas, 
and polarities and compositions that are more 
characteristic for oligomer interfaces than for 
crystal packing contacts.28, 29 The tetramer dis-
plays only C2 (two-fold) rather than the custom-
ary D2 (222) symmetry. The center of the tetramer 
is open, and the chains are held together by just 
two kinds of interfaces. The symmetry and pack-
ing of the subunits predict that the tetramers will 
dissociate to dimers, as observed in gel filtration 
of dilute enzyme solutions. The area calculated for 
the B−C interface is 800 Å2, while that for the A−B 
interface is 500 Å2; this suggests that the tetramer 
will dissociate into identical A-A’ and B-C dimers, 
across the interface that incorporates helix α5. 
Thus if steric overlap of Val 177 with its neighbors 
triggers movement of helix α5, the interactions 
across this interface will be affected.
Implications
Our comparison of the phenotypes of wild-
type and A177V mutant MTHFR enzymes from 
E. coli suggests that the mutation leads to a ther-
molabile enzyme that loses its flavin cofactor more 
readily than does the wild type. This mutation 
accentuates properties inherent in the wild-type 
enzyme. With both wild-type and mutant enzymes, addition 
of folate derivatives results in decreased rates of flavin release 
and activity loss. We envision that protection by folate results 
from the increased affinity of MTHFR for FAD in the ternary 
complexes of enzyme, folate, and FAD.
The structure/function studies of the bacterial enzyme re-
ported here provide a model for the role of folic acid in ame-
liorating hyperhomocysteinemia in humans, especially those 
homozygous for the A222V mutation. Although the human 
enzyme has not been fully characterized biochemically, our 
experiments (Figure 7) indicate that addition of methyltetra-
hydrofolate or FAD protects the human wild-type and mu-
tant enzymes against thermal inactivation. The upper panel 
shows the protective effect of these compounds in crude ex-
tracts containing recombinant human enzyme expressed in E. 
coli1, while in the lower panel lymphocyte extracts from Ala/
Ala (normal MTHFR) or Val/Val (mutant MTHFR) human 
subjects have been used. Addition of FAD to crude extracts 
protects both wild-type and mutant enzymes, and the pro-
tection is more dramatic with the mutant enzyme. Addition 
of methyltetrahydrofolate to the crude extracts also protects 
both the wild-type and mutant enzymes against thermal dena-
turation, with the more dramatic protection again being seen 
with the mutant enzyme. In vivo, increased concentrations of 
folate derivatives that are products or inhibitors of the reaction 
will inhibit the reduction of CH2-H4 folate as well as stabiliz-
ing the enzyme. However, we assume that supplementation 
with folic acid increases the concentration of all intracellular 
Figure 3. The FAD-binding site. a) The electron density 
in the vicinity of the cofactor, contoured at 1σ. The map 
was calculated with amplitudes (2|Fo| - |F c|) and phases 
from the final refinement (Table 1); contours within 3 Å 
of model atoms are displayed. Residues surrounding 
the exposed si face are His 88, Asp 120, Thr 182 and Gln 
183; β-strand 2 is in the foreground. b) A stereo draw-
ing showing many of the conserved residues that contact 
bound FAD, which is drawn in ball-and-stick mode with 
atom coloring. Side-chain carbons are in cyan with oxy-
gen and nitrogen atoms red and blue, respectively. The 
belt residues, Arg 118 and Glu 158, are distinguished by 
darker stick bonds and dot surfaces.
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folate derivatives, including the substrate CH2 -H4 folate. The 
results reported here suggest that increased folate, known to 
lower homocysteine levels in normal subjects11 and in A→V 
homozygotes,6 acts by suppressing loss of FAD from MTHFR.
Recent studies have demonstrated that folate deficiency 
in humans leads to uracil misincorporation into DNA and 
chromosome breakage, and have suggested that the 677C→T 
polymorphism might provide protection against chromo-
some breakage when the concentration of intracellular folates 
is low by sequestering folate in the CH2-H4 folate form that 
is required for conversion of dUMP to dTMP.30 If the level 
of methylenetetrahydrofolate is low and MTHFR is fully ac-
tive, flux will favor methionine biosynthesis over synthesis of 
thymidylate. Our studies suggest that wild-type MTHFR re-
sponds to low folate levels by undergoing flavin loss and in-
activation. Our observations on bacterial and human MTHFR 
provide a biochemical rationale for the effects of folate supple-
ments in reducing plasma homocysteine levels in individuals 
homozygous for the polymorphism. In addition, since folate 
derivatives stabilize both the wild-type and mutant enzymes, 
the benefit of folate supplementation should extend to indi-
viduals who are not homozygous for the polymorphism. Re-
cent clinical studies suggest that individuals who are homo-
zygous for the polymorphism might be particularly sensitive 
to homocysteine lowering by folate, although nonmutant in-
dividuals do respond.31 Our results suggest that the activity 
of both wild-type and mutant enzymes may be controlled by 
the intracellular folate and FAD concentrations, and that the 
677C→T mutation simply shifts the balance point at which en-
zyme inactivation occurs. 
Methods
Overexpression and purification of wild-type and A177V mu-
tant MTHFR. 
Wild-type MTHFR was purified to homogeneity from E. coli strain 
CAS-9 as described.24 Briefly, the coding sequence was placed into the 
polylinker region of plasmid pTrc99A (Pharmacia) and transformed into 
metF strain AB1909, which lacks a functional MTHFR and is auxotro-
phic for methionine, for overexpression. MTHFR was purified to homo-
geneity by batch chromatography on DEAE fast-flow Sepharose, FPLC 
on Mono Q anion-exchange resin, and hydrophobic FPLC on Phenyl 
Sepharose. This enzyme was used for structure determination. How-
ever, attempts to express the A177V protein in a similar manner led 
to very low levels of expression, and the protein was too unstable to 
survive the purification procedure. We therefore constructed strains 
expressing C-terminally histidine(6)-tagged wild-type24 and A177V 
MTHFR. Plasmids containing the coding sequences for these proteins 
were used to transform E. coli strain BL21(DE3)recD+ (Novagen). This 
strain contains a functional metF gene but only 1% of the MTHFR pro-
tein is wild-type and lacks the histidine tag. Histidine-tagged MTHFR 
from these strains could be purified to homogeneity in a single step 
Figure 4. The A177V mutation leads to a thermolabile enzyme as 
assessed by differential-scanning calorimetry. Measurements were 
performed on wild-type and A177V MTHFR proteins at the indicated 
subunit concentrations. Each data set has been offset by 20 kcal mol−1 
K−1 for clarity, and the melting temperatures (Tm) are displayed along-
side their respective peaks. A preliminary experiment in which the Tm 
values of 22 μM wild-type and wild-type histidine-tagged MTHFR pro-
teins were compared gave values of 58.4 and 58.6 °C, respectively, in-
dicating that the His6 tag at the C-terminus did not affect the melting 
temperature.
Figure 5. a) The A177V mutation is associated with an enhanced rate of flavin dissociation. After dilution of a concentrated stock of enzyme 
to the indicated subunit concentrations [Et], the initial rate of FAD dissociation was ascertained for wild-type (●) and A177V (■) enzymes. The solid 
lines have been calculated assuming that the rate of flavin release varies as the square root of the enzyme concentration after dilution. Inset: The 
change in fluorescence versus time is shown for wild-type (lower trace) and A177V (upper trace) enzymes diluted to 500 nM concentration. b) Pro-
tection of wild-type and A177V mutant enzyme against flavin loss after dilution in the presence of CH3-H4 folate. The initial rate of flavin loss from 
500 nM wild-type (●) and A177V mutant (■) enzymes is plotted against the concentration of (6S)CH3-H4 folate monoglutamate (Eprova Pharma-
ceuticals) present after dilution. The initial rates have been corrected for fluorescence increases associated with the slow oxidation of CH3-H4 folate 
catalyzed by the enzyme under aerobic conditions.
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by chromatography on Hi-Trap nickel agarose columns as described,24 
and yielded enzymes with a full complement of bound FAD (four per 
tetramer)24 and with comparable specific activity as measured by CH2-
H4 folate-menadione oxidoreductase assay.
Structure determination. The structure of E. coli MTHFR was de-
termined by multiwavelength anomalous diffraction32 (MAD) using 
mercury as the anomalous scatterer. Crystals suitable for data col-
lection were obtained from 15% isopropanol, 100 mM MES pH 6.1, 
40 μM FAD, 160 mM ammonium sulfate, and 8−13% poly-
ethylene glycol (M r 8,000) at 4 °C, and belong to space 
group C2 with unit cell dimensions a = 103.00 Å, b = 128.20 
Å, c = 98.20 Å, and β = 121.60°, with three chains in the 
asymmetric unit. The MAD experiment (three wavelengths) 
was performed at CHESS beamline F2 with a crystal soaked 
in mercuric acetate and flash frozen. The CCP4 suite of pro-
grams33 was used to locate the mercury sites by Patterson 
methods. Phases were calculated using the MAD option 
of MLPHARE33 (<m> = 0.44−2.9 Å), and solvent flattening 
was performed with DM33. The model building for the three 
chains in the asymmetric unit was done in O.34 X-PLOR35 was 
used for refinement of the model in rounds that included 
simulated annealing and refinement of individual atom B-
factors. A bulk solvent correction was applied.36
Differential-scanning calorimetry. Differential-scan-
ning calorimetry was performed by Craig Johnson of Calo-
rimetry Sciences Corporation on a NANO differential-scan-
ning calorimeter. The excess heat capacity <C p> for thermal 
denaturation of purified enzyme in 50 mM potassium phos-
phate buffer, pH 6.3, containing 0.3 mM EDTA and 10% 
glycerol was measured for the indicated concentrations of 
wild-type and A177V histidine-tagged proteins over a tem-
perature range from 15 to 75 °C. The temperature was in-
creased at 1 °C min−1.
Fluorimetry. Concentrated enzyme (~200 mM) was di-
luted to concentrations between 0.25 and 7 μM and the in-
crease in fluorescence, a measure of FAD dissociation, was 
monitored over time. Fluorescence was measured with exci-
tation at 390 nm and emission at 525 nm in an ISA JY/SPEX 
fluorimeter. 
Coordinates. The coordinates have been deposited in 
the Protein Data Bank (accession code 1B5T).
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Figure 6.  a) The location and environment of the Ala 177 that corresponds 
to the site of the A→V polymorphism in human MTHFR. The view is approxi-
mately perpendicular to the barrel axis and oriented to show helix α5 and its neigh-
boring barrel strands. Black dot surfaces trace the helix backbone from 171 to 176; 
red surfaces represent the volume of alanine at position 177, and green surfaces a 
valine substituted at position 177 which clearly overlaps the helix backbone. The 
side chains of Lys 172, Asn 168, and Asp 165 that interact with FAD are drawn in 
ball-and-stick mode with carbons in cyan. b) The tetramer of E. coli MTHFR, viewed 
down the local two-fold axis. The asymmetric unit of the monoclinic cell contains 
the three chains A, B, and C; the fourth chain of the tetramer (A’) is related to A by a 
crystallographic two-fold axis. The C and B subunits can be superimposed on chains 
A and A’ by a local dyad (perpendicular to the page) that is inclined by ~53° to the 
crystallographic dyad along axis y. This local dyad is the only symmetry operator 
that relates the chains of the tetramer to one another. Interfaces A−A’ and B−C are 
formed by symmetric interactions between helices α7c, α7b, and α8. In contrast, the 
A and B (or C and A’) chains are not related by a simple rotation of 360/nO; the B 
chain is superimposed on the A chain by a rotation of 108° and a translation of ~7 
Å. Helix 5, which may be critical in mediating the effects of mutation at position 177, 
is drawn in red, and Ala 177 is white and surrounded by dot surfaces. The figure was 
prepared using the program RIBBONS.37
Figure 7. Stabilization of normal and mutant human 
MTHFR (hMTHFR) by CH 3-H4 folate and FAD against 
heat inactivation. In each panel, the dark-gray columns 
represent data obtained for normal (Ala) MTHFR, while 
the light-gray stippled columns represent data obtained 
for mutant (Val) MTHFR. a,b) Stabilization of recombi-
nant wild-type and A222V MTHFR expressed in E. coli1. 
Aliquots of crude sonicate supernatants containing 100 
μg protein were preincubated at 46 °C in the presence of 
the indicated concentrations of (6-RS)CH3-H4 folate (a) or 
FAD ( b). After cooling to 37 °C, additional (6-RS)CH3-H4 
folate and/or FAD were added to the reaction mixtures 
and the samples were assayed in duplicate using the CH3-
H4 folate-menadione oxidoreductase assay
1, 38. Values re-
ported have been corrected for the activity in a control 
JM105 strain1. The bars represent the mean ±s.d. of data 
obtained from three experiments. c, d) Stabilization of 
normal (Ala/Ala) and mutant (Val/Val) MTHFR in human 
lymphocyte extracts (90 μg of protein) by CH3-H4 folate 
(c) and FAD (d). The bars represent the mean ±s.d. of data 
obtained from duplicate assays of the enzyme extracts of 
three individuals.
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Table 1. X-ray data collection, MAD phasing, and structure refinement
Data collection
Crystal  Wavelength (Å)  Resolution (Å)  Completeness (%)  No. of observations  Unique reflections  Rsym
1
λ1  1.012  2.5  97.3 (81.4)  375,635  36,377  0.060 (0.091)
λ2  1.010  2.5  97.2 (80.4)  376,949  36,492  0.066 (0.097)
λ3  1.008  2.5  97.3 (83.0)  377,615  36,508  0.068 (0.101)
MAD phasing
Resolution (Å)2  13.64  8.92  6.63  5.27  4.38  3.74  3.27  2.90
<m>  0.462  0.423  0.499  0.513  0.454  0.412  0.434  0.435
Statistics after refinement
Resolution (Å)  20.0–2.5  Rwork  0.212
Reflections3  36,486  Rfree  0.263
Protein + FAD atoms  6,378  Deviations in
Solvents  184      Bond length  0.008 Å
Average B (protein)  21.36 Å2      Bond angles  1.4°
Average B (solvents)  26.20 Å2      Improper dihedrals  1.2°
1. Values in parentheses are for outermost bins.
2. High-resolution limit for bins.
3. No σ cutoff.
